News

Richard Lafeyette, MD, discusses his reaction to the phase 3 ORIGIN topline results and what it means for IgAN.

GLP-1 RAs, one of the most common medications for obesity and diabetes, have several inherent risks that are often overlooked in favor of their efficacy.

The month in review spotlights hepatic podcast episodes from HCPLive, new clinical trial data, and coverage from DDW.

Immunization is underused in IBD care despite high infection risks from immunosuppressants—early, proactive vaccination is essential for prevention.

Investigators compared the medications across various patient cohorts with different causes of anemia, finding evidence almost uniformly in favor of FCM.

UK study finds atopic conditions, especially anaphylaxis, significantly raise the risk of anxiety, depression, OCD, and other mental illnesses in primary care patients.

This video includes a discussion of different procedures designed to help treat patients with hidradenitis suppurativa (HS) and atopic dermatitis.

Combination therapy with finerenone and empagliflozin significantly reduces urinary albumin levels in CKD patients.

This recent study highlights the intricate variations between glaucoma cases, encouraging a more individual approach to analyzing treatment responses.

New 100-week data reveals zigakibart's significant efficacy and safety in reducing proteinuria for IgA nephropathy.

Get an overview of the top stories from May 2025 in endocrinology in our monthly recap!

Asthma and peanuts were identified as key risk factors for grade 4 anaphylaxis in a retrospective study, highlighting the need for tailored prevention.

Alkhouri reviews data from the trial’s open-label compensated MASH cirrhosis arm demonstrating resmetirom’s impact on liver stiffness and CSPH.

If approved, lamivudine may bring DME treatment and better vision outcomes to communities who cannot afford more costly intravitreal injections.

An overview of the 7 presentations included as late-breaking clinical trials at ERA 2025.

Sciurba shared his excitement for the recent approval of mepolizumab for people with COPD and an eosinophilic phenotype.

These findings were announced by Sagimet Biosciences, showing that denifanstat met each of its primary and secondary endpoints in patients with acne.

This interview with Steven Daveluy, MD, features a discussion of hidradenitis suppurativa, cutaneous lymphoma, and addressing racial disparities.

A recent study reveals no link between cesarean delivery and childhood allergies, challenging previous findings and highlighting Japan's unique health context.

Hosts discuss a consensus repot from the ADA focused on screening and early interview of MASLD in people with diabetes.

A recent analysis reveals no significant difference between restrictive and liberal transfusion strategies on quality of life in patients with myocardial infarction and anemia.

This prospective observational study suggests that there are differences between the gut microbiome compositions of pediatric patients and others with HS.

Check out these 7 late-breaking abstracts to watch at the upcoming SLEEP 2025 meeting.

A relatively quiet month for hematology, marked by brief ups and downs for trials and new research on anemia and sickle cell disease.

New data support the “two-hit” hypothesis: early allergic sensitization plus respiratory infections may impair lung function into adulthood, up to age 25 years.

During his New Wave Dermatology interview, Naveed Sami, MD, spoke about additional takeaways from his session on the cutaneous effects of immunotherapies.

Discover key advancements and setbacks in cardiovascular medicine from May 2025, shaping the future of cardiometabolic care and treatment options.